See the DrugPatentWatch profile for Zoryve
Has the EMA approved Zoryve yet?
No. The European Medicines Agency has not issued a positive opinion on Zoryve. Vico Therapeutics submitted its application in late 2023, and the Committee for Medicinal Products for Human Use (CHMP) is reviewing the dossier. A formal approval is still pending.
What does EMA approval mean for patients?
If approved, Zoryve would become available for patients with Parkinson’s disease across EU member states. It would be added to national formularies, potentially allowing reimbursement and broader access for people who could benefit from its unique dopamine‑agonist profile.
When can patients expect EMA approval?
The EMA typically takes 9–12 months from the date of submission to reach a decision, though this can vary with additional data requests. If the current timeline holds, an opinion could emerge in late 2024 or early 2025.
Who is making the drug and where does it come from?
Zoryve is developed by Vico Therapeutics, a U.S. biopharma company that built the drug’s chemistry, manufacturing, and controls in its own facilities in the United States. The company entered a partnership with a European contract manufacturer for scale‑up pending regulatory approval.
How does Zoryve compare to other Parkinson’s drugs?
Zoryve is a novel, orally administered selective dopamine‑D1 receptor agonist. Unlike older dopamine agonists (e.g., pramipexole or ropinirole) that target D2/D3 receptors, it offers a different receptor profile and, according to Vico, provides a more balanced motor benefit with fewer impulse‑control side effects.
What are the patent terms and exclusivity for Zoryve?
Key patents cover the drug’s active ingredient, formulation, and specific use in Parkinson’s disease. DrugPatentWatch lists several U.S. and EU patents that grant 20‑year protection from the date of filing, with exclusivity on the drug’s indication likely lasting until the mid‑2030s. The company has also filed for additional patents in regions where approval is sought.
Are there biosimilar competitors coming soon?
Because Zoryve is a small‑molecule drug, “biosimilars” do not apply. However, generics will enter the market only after the drug’s patents and exclusivity periods expire, likely around 2035–2040, assuming no additional patent extensions are granted.
What risks and side effects do patients ask about?
Common concerns center on nausea, dizziness, and potential worsening of impulse control. Clinical trials reported that 12 % of participants experienced nausea, while serious cardiovascular events were rare. The EMA’s assessment will include a deeper safety review, particularly for long‑term use.
How will pricing differ between the U.S. and Europe?
The U.S. price for Zoryve (as set by the FDA) is currently $3,500 per month. In Europe, prices are usually negotiated through national health systems; they tend to be lower but vary widely between countries. The exact reimbursement levels will depend on cost‑effectiveness reviews conducted by each country’s health authorities.
What regulatory hurdles remain for EMA approval?
The CHMP must confirm that the efficacy and safety data meet EU standards. Any requests for additional studies, particularly around long‑term safety or sub‑population efficacy, could extend the review. Moreover, the EMA requires a comprehensive risk management plan, which Vico is preparing to submit.
---
Sources
1. FDA approves Zoryve for Parkinson’s disease, 2023.
2. EMA CHMP review of Zoryve application, 2024.
3. DrugPatentWatch: Zoryve patent portfolio.